DOCSLIB.ORG

CURRICULUM VITAE JEFFREY L. CUMMINGS, M.D., Sc.D

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
CURRICULUM VITAE JEFFREY L. CUMMINGS, M.D., Sc.D CURRICULUM VITAE JEFFREY L. CUMMINGS, M.D., Sc.D. December 14, 2016 TABLE OF CONTENTS PERSONAL HISTORY: ................................................................................................................................................................................. 2 EDUCATION: ................................................................................................................................................................................................. 2 PROFESSIONAL EXPERIENCE: .................................................................................................................................................................. 2 BOARD CERTIFICATION: ........................................................................................................................................................................... 3 MEDICAL LICENSURE: ............................................................................................................................................................................... 3 HONORS AND AWARDS: ............................................................................................................................................................................ 4 PROFESSIONAL ACTIVITIES: .................................................................................................................................................................... 5 SOCIETIES AND AFFILIATIONS: .............................................................................................................................................. 5 MISCELLANEOUS: ...................................................................................................................................................................... 7 INTERNATIONAL POSITIONS: .................................................................................................................................................. 8 NIH ALZHEIMER'S DISEASE CENTER GROUP: ..................................................................................................................... 8 ALZHEIMER’S ASSOCIATION: ................................................................................................................................................. 9 INTERNATIONAL ADVISORY BOARDS: ................................................................................................................................ 9 UCLA NEUROBEHAVIOR AND DEMENTIA FELLOWS: ...................................................................................................................... 10 UCLA INTERNATIONAL SCHOLARS: .................................................................................................................................................... 10 CLEVELAND CLINIC LOU RUVO CENTER FOR BRAIN HEALTH SCHOLARS: .............................................................................. 10 UCLA PH.D. DISSERTATION COMMITTEES: ........................................................................................................................................ 10 FOUNDATIONS: .......................................................................................................................................................................................... 11 JOURNAL AND TEXTBOOK BOARDS AND SERVICES: ...................................................................................................................... 11 PROPOSAL REVIEW SERVICES: .............................................................................................................................................................. 14 FUNDED RESEARCH: ................................................................................................................................................................................ 14 INDUSTRY-SPONSORED RESEARCH AND CLINICAL TRIALS: ........................................................................................................ 15 FOUNDATION AND ALZHEIMER’S DISEASE COOPERATIVE STUDY (ADCS) TRIALS: .............................................................. 17 INDUSTRY RELATED EXPERIENCE: ...................................................................................................................................................... 18 PUBLICATIONS: ......................................................................................................................................................................................... 19 Books .............................................................................................................................................................................................19 Articles ...........................................................................................................................................................................................20 Multicenter Publications to which Dr. Cummings was a Contributor ...........................................................................................58 Cleveland Clinic Publications ........................................................................................................................................................60 Chapters .........................................................................................................................................................................................60 Monographs ...................................................................................................................................................................................72 Abstracts ........................................................................................................................................................................................72 Book Cover Citations.....................................................................................................................................................................96 Book Reviews ................................................................................................................................................................................96 Forewords ......................................................................................................................................................................................97 Other ..............................................................................................................................................................................................97 MEDIA/VIDEOS: ......................................................................................................................................................................................... 99 SELECTED NATIONAL PRESENTATIONS/NAMED LECTURESHIPS: ............................................................................................... 99 SELECTED INTERNATIONAL PRESENTATIONS: .............................................................................................................................. 101 1 C U R R I C U L U M V I T A E PERSONAL HISTORY: NAME: JEFFREY L. CUMMINGS, M.D., Sc.D. TITLE: Director, Cleveland Clinic Lou Ruvo Center for Brain Health Camille and Larry Ruvo Chair for Brain Health Cleveland Clinic Neurological Institute Las Vegas, Nevada; Cleveland, Ohio; Weston, Florida Professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western University Adjunct Professor of Psychology, College of Liberal Arts, University of Nevada, Las Vegas Adjunct Clinical Professor of Neurology, University of Nevada Las Vegas School of Medicine BUSINESS ADDRESS: Cleveland Clinic Lou Ruvo Center for Brain Health 888 W. Bonneville Avenue Las Vegas, NV 89106 T: 702.483.6029 F: 702.483.6028 EDUCATION: Baccalaureate University of Wyoming, graduation with High Honors, Bachelor of Science (Zoology), l966 – l970 MD University of Washington School of Medicine, Seattle, Washington, M.D., l970 – 1974 ScD University of Wyoming Laramie, Wyoming Bestowed 2011 Internship Flexible Internship, Hartford Hospital, Hartford, Connecticut, 1974 – l975. Residency Neurology, Boston University School of Medicine, Boston, Massachusetts, l975 – 1978 Fellowship I Behavioral Neurology, Boston University School of Medicine, Boston, Massachusetts, l978 – 1979 Fellowship II Postgraduate studies in Neuropathology and Neuropsychiatry, Institute of Neurology National Hospital for Neurological Diseases Queen Square, London, England, l980 DATE OF BIRTH: March 8, l948 PLACE OF BIRTH: Basin, Wyoming CITIZENSHIP: United States PROFESSIONAL EXPERIENCE: 2 Boston University School of Medicine 1978 – 1979 Chief Resident in Neurology, Instructor in Neurology, Boston University School of Medicine Instructor, Clinical Medicine (Neurology), Laboure Junior College, Boston, Massachusetts 1979 – 1980 Director of Behavioral Neurology, Boston University Medical Center; Assistant Professor of Neurology, Boston University School of Medicine Consultant in Neurology, VAMC Boston Physician Coordinator, Wald Neurological Unit, Boston University Medical Center Department of Veterans Affairs 1980 – 1990 Director, Neurobehavior Unit, West Los Angeles VAMC (Brentwood Division) 1981 – 1988 Chief of Medicine, West Los Angeles VAMC (Brentwood Division) 1984 – 1988 Assistant Clinical Director, Nursing Home Care Unit, West Los Angeles VAMC 1986 – 199l Co-Chief, Movement Disorders Laboratories, West Los Angeles
Load more

Recommended publications
  • Neuropathology of Dementia in Patients with Parkinson's Disease: a Systematic Review of Autopsy Studies
    Neurodegeneration J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp-2019-321111 on 23 August 2019. Downloaded from REVIEW Neuropathology of dementia in patients with Parkinson’s disease: a systematic review of autopsy studies Callum Smith ,1 Naveed Malek,2 Katherine Grosset,1 Breda Cullen ,3 Steve Gentleman,4 Donald G Grosset1 ► Additional material is ABSTRact have other causes of cognitive impairment and published online only. To view Background Dementia is a common, debilitating dementia, such as comorbid Alzheimer’s disease please visit the journal online (http:// dx. doi. org/ 10. 1136/ feature of late Parkinson’s disease (PD). PD dementia (AD) or cerebrovascular disease. These pathologies jnnp- 2019- 321111). (PDD) is associated with α-synuclein propagation, but may be difficult to identify in vivo, as the clinical coexistent Alzheimer’s disease (AD) pathology may features often overlap with those of PDD, and there 1 Department of Neurology, coexist. Other pathologies (cerebrovascular, transactive are no definitive biomarkers. The differentiation Institute of Neurosciences, response DNA-binding protein 43 (TDP-43)) may of dementia type is an important consideration in Queen Elizabeth University Hospital, Glasgow, UK also influence cognition.W e aimed to describe the clinical research, as treatments under development 2Department of Neurology, neuropathology underlying dementia in PD. are specifically targeted against abnormal accumu- Ipswich Hospital NHS Trust, Methods Systematic review of autopsy studies lation of α-synuclein, which is the pathological Ipswich, UK 3 3 published in English involving PD cases with dementia. hallmark of PDD and DLB, or tau or amyloid-β, Institute of Health and 4 5 Wellbeing, College of Medical, Comparison groups included PD without dementia, AD, which underlie AD.
    [Show full text]
  • Effect of Dextromethorphan-Quinidine on Agitation in Patients with Alzheimer Disease Dementia a Randomized Clinical Trial
    Research Original Investigation Effect of Dextromethorphan-Quinidine on Agitation in Patients With Alzheimer Disease Dementia A Randomized Clinical Trial Jeffrey L. Cummings, MD, ScD; Constantine G. Lyketsos, MD, MHS; Elaine R. Peskind, MD; Anton P. Porsteinsson, MD; Jacobo E. Mintzer, MD, MBA; Douglas W. Scharre, MD; Jose E. De La Gandara, MD; Marc Agronin, MD; Charles S. Davis, PhD; Uyen Nguyen, BS; Paul Shin, MS; Pierre N. Tariot, MD; João Siffert, MD Editorial page 1233 IMPORTANCE Agitation is common among patients with Alzheimer disease; safe, effective Author Video Interview and treatments are lacking. JAMA Report Video at jama.com OBJECTIVE To assess the efficacy, safety, and tolerability of dextromethorphan Supplemental content at hydrobromide–quinidine sulfate for Alzheimer disease–related agitation. jama.com DESIGN, SETTING, AND PARTICIPANTS Phase 2 randomized, multicenter, double-blind, CME Quiz at jamanetworkcme.com and placebo-controlled trial using a sequential parallel comparison design with 2 consecutive CME Questions page 1286 5-week treatment stages conducted August 2012–August 2014. Patients with probable Alzheimer disease, clinically significant agitation (Clinical Global Impressions–Severity agitation score Ն4), and a Mini-Mental State Examination score of 8 to 28 participated at 42 US study sites. Stable dosages of antidepressants, antipsychotics, hypnotics, and antidementia medications were allowed. INTERVENTIONS In stage 1, 220 patients were randomized in a 3:4 ratio to receive dextromethorphan-quinidine (n = 93) or placebo (n = 127). In stage 2, patients receiving dextromethorphan-quinidine continued; those receiving placebo were stratified by response and rerandomized in a 1:1 ratio to dextromethorphan-quinidine (n = 59) or placebo (n = 60).
    [Show full text]
  • WO 2016/001643 Al 7 January 2016 (07.01.2016) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2016/001643 Al 7 January 2016 (07.01.2016) P O P C T (51) International Patent Classification: (74) Agents: GILL JENNINGS & EVERY LLP et al; The A61P 25/28 (2006.01) A61K 31/194 (2006.01) Broadgate Tower, 20 Primrose Street, London EC2A 2ES A61P 25/16 (2006.01) A61K 31/205 (2006.01) (GB). A23L 1/30 (2006.01) (81) Designated States (unless otherwise indicated, for every (21) International Application Number: kind of national protection available): AE, AG, AL, AM, PCT/GB20 15/05 1898 AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, (22) International Filing Date: DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, 29 June 2015 (29.06.2015) HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (25) Filing Language: English KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, (26) Publication Language: English PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, (30) Priority Data: SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, 141 1570.3 30 June 2014 (30.06.2014) GB TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. 1412414.3 11 July 2014 ( 11.07.2014) GB (84) Designated States (unless otherwise indicated, for every (71) Applicant: MITOCHONDRIAL SUBSTRATE INVEN¬ kind of regional protection available): ARIPO (BW, GH, TION LIMITED [GB/GB]; 39 Glasslyn Road, London GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, N8 8RJ (GB).
    [Show full text]
  • Internet Resources for Neurosurgeons and Neuropathologists S Thomson, N Phillips
    154 J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp.74.2.154 on 1 February 2003. Downloaded from REVIEW Internet resources for neurosurgeons and neuropathologists S Thomson, N Phillips ............................................................................................................................. J Neurol Neurosurg Psychiatry 2003;74:154–157 Neurosurgical and neuropathological resources on the Neurosurgery://On-call has an “image bank” internet are rapidly developing. Some excellent clinical, section, which has an excellent downloadable collection of radiographs. There are also some patient information, professional, academic, and photographic images. This is a rapidly developing teaching web sites are available. This review database, easy to search, and likely to have images summarises the most useful online sites for relevant to most neurosurgical and neuropatho- logical conditions. neurosurgeons and neuropathologists in the United Neuroanatomy and Neuropathology on the Kingdom and beyond. More general internet resources Internet provides a very comprehensive collection of pathological images within the online neu- have been covered in the first article in this series. ropathology atlas. The neuroanatomy structures .......................................................................... subsection shows the locations of anatomical structures within normal pathological specimens. ver the past 10 years the internet has The functional neuroanatomy tables are also expanded rapidly. While potential ben- highly
    [Show full text]
  • Neuromuscular Medicine Core Competencies Outline
    The American Board of Psychiatry and Neurology Neuromuscular Medicine Core Competencies Outline I. Neuromuscular Patient Care Core Competencies A. GENERAL: Neuromuscular Medicine Specialists shall demonstrate the following abilities: 1. To perform and document relevant history and examination of culturally diverse patient to include as appropriate: a. Chief complaint b. History of present illness c. Past medical history d. Developmental history (especially for children) e. Comprehensive review of both neurologic and general systems f. Biological family history g. Sociocultural history h. Neurological examination and a germane general examination as appropriate to the present illness 2. Delineate appropriate differential diagnoses 3. Formulate, assess and recommend effective management B. FOR NEUROMUSCULAR MEDICINE: Based on comprehensive neurological assessments, Neuromuscular Specialists shall demonstrate the following abilities: 1. To determine: a. If a patient’s symptoms are the result of a disease affecting the central and/or peripheral nervous system or are of another origin (e.g., of a systemic, psychiatric, or psychogenic illness) by performing appropriate neuromuscular evaluation b. An initial diagnostic formulation with differential diagnosis c. Appropriate diagnostic modalities to include laboratory blood, urine, and cerebrospinal fluid analyses, electrodiagnostic, imaging, genetic, and pathologic investigations to evaluate and manage such patients d. Management plan 2. To develop and maintain the technical skills to: a. Perform
    [Show full text]
  • P:\Autism Cases\Dwyer 03-1202V\Opinion Segments NEW
    IN THE UNITED STATES COURT OF FEDERAL CLAIMS OFFICE OF THE SPECIAL MASTERS No. 03-1202V Filed: March 12, 2010 ******************************************************* TIMOTHY and MARIA DWYER, parents of * COLIN R. DWYER, a minor, * Omnibus Autism Proceeding; * Theory 2 Test Case; Petitioners, * Thimerosal-Containing Vaccines; * Ethylmercury; Causation; v. * “Clearly Regressive” Autism; * Oxidative Stress; Sulfur SECRETARY OF THE DEPARTMENT OF * Metabolism Disruption; HEALTH AND HUMAN SERVICES, * Excitotoxicity; Expert * Qualifications; Weight of the Respondent. * Evidence * ******************************************************* DECISION1 James Collins Ferrell, Esq., Houston, TX; Thomas B. Powers, Esq. and Michael L. Williams, Esq., Portland, OR; for petitioners. Lynn Elizabeth Ricciardella, Esq. and Voris Johnson, Esq., U.S. Department of Justice, Washington, DC, for respondent. VOWELL, Special Master: On May 14, 2003, Timothy and Maria Dwyer [“petitioners”] filed a “short form” petition for compensation under the National Vaccine Injury Compensation Program, 42 U.S.C. § 300aa-10, et seq.2 [the “Vaccine Act” or “Program”], on behalf of their minor 1 Vaccine Rule 18(b) provides the parties 14 days to request redaction of any material “(i) which is trade secret or commercial or financial information which is privileged and confidential, or (ii) which are medical files and similar files, the disclosure of which would constitute a clearly unwarranted invasion of privacy.” 42 U.S.C § 300aa12(d)(4)(B). Both parties have waived their right to request such redaction. See Petitioners’ Notice to Waive the 14-Day Waiting Period, filed February 1, 2010; Respondent’s Consent to Disclosure, filed January 13, 2010. Accordingly, this decision will be publically available upon filing. 2 National Childhood Vaccine Injury Act of 1986, Pub.
    [Show full text]
  • Stanford University Neuroradiology Fellowship
    STANFORD UNIVERSITY NEURORADIOLOGY FELLOWSHIP The neuroradiology fellowship at Stanford University Medical Center is designed to be a well-balanced academic training program that encompasses all of the basic and advanced clinical and research areas of both adult and pediatric neuroradiology. The overall aims of this fellowship are two-fold: to produce neuroradiologists with the highest level of clinical expertise, and to produce the future leaders in academic neuroradiology. The goal of this fellowship program is for Neuroradiology fellows to develop knowledge, skills and attitudes necessary to properly evaluate, diagnose and manage patients with neurological, ENT and neurosurgical diseases. Therefore, this fellowship requires participation in clinical, research, and educational aspects of neuroradiology. Neuroradiology fellows will be exposed to all imaging modalities used to evaluate neurologic disease, including CT, MR, myelography, angiography, and imaging guided biopsies, during the course of the fellowship. Interventional neuroradiologic procedures are also performed at state-of-the-art levels at Stanford, and neuroradiology fellows will actively participate in these procedures. Goal of the Neuroradiology Fellowship Program Core Competencies Fellows should achieve the Interpersonal System following objectives: and -Based Patient Medical Practice-Based Communicati Professional Learni Care Knowledge Learning on Skills ism ng 1. Acquire specific knowledge about the physical principles of imaging modalities (CT,MR,ultrasound and digital subtraction angiography). X X 2. Identify the practical uses of CT, MR, ultrasound and digital subtraction angiography in the evaluation of neurologiocal, ENT and neurosurgical diseases. X X X 3. Develop thorough knowledge of the physical and physiological properties of contrast agents used in CT, MR, and angiography; including contraindications and management of potential complications.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,605,007 B2 Brodney Et Al
    US009605.007 B2 (12) United States Patent (10) Patent No.: US 9,605,007 B2 Brodney et al. (45) Date of Patent: *Mar. 28, 2017 (54) 2-AMINO-6-METHYL-4.4A,5,6- 8,822,456 B2 9/2014 Brodney et al. 8,933,221 B2 1/2015 Brodney et al. TETRAHYDROPYRANO3,4-D1.3THIAZIN 8,962,616 B2 2/2015 Brodney et al. 8A(8H)-YL-1,3-THIAZOL-4-YL AMIDES 9,045,498 B2 6/2015 Brodney et al. 9,045.499 B2 6/2015 Brodney et al. (71) Applicant: Pfizer Inc., New York, NY (US) 9,192,612 B2 11/2015 Brodney et al. 9,198.917 B2 12/2015 Brodney et al. (72) Inventors: Michael Aaron Brodney, Newton, MA 9,233,981 B1 1/2016 Brodney et al. 9,315.520 B2 * 4/2016 Brodney .............. CO7D 513/04 (US); Elizabeth Mary Beck, Edinburgh 9,428,523 B2 * 8/2016 Brodney .............. CO7D 519.00 (GB); Christopher Ryan Butler, 2003/OO73655 A1 4/2003 Chain Canton, MA (US); Lei Zhang, 2003/O195205 A1 10/2003 DeNinno et al. Auburndale, MA (US); Brian Thomas 2004/0192898 A1 9, 2004 Jia et al. O'Neill, Haddam, CT (US); Gabriela 2004/022O186 A1 11/2004 Bell et al. 2005, OO19328 A1 1/2005 Schenk et al. Barreiro, São Paulo (BR): Erik Alphie 2005, 0043354 A1 2/2005 Wager et al. LaChapelle, Uncasville, CT (US); 2005/0048049 A1 3/2005 Schenk et al. Bruce Nelsen Rogers, Belmont, MA 2005/0256135 A1 11/2005 Lunn et al. (US) 2005/0267,095 A1 12/2005 Bernardelli et al.
    [Show full text]
  • Neuropathology Review.Pdf
    Neuropathology Review Richard A. Prayson, MD Humana Press Contents NEUROPATHOLOGY REVIEW 2 Contents Contents NEUROPATHOLOGY REVIEW By RICHARD A. PRAYSON, MD Department of Anatomic Pathology Cleveland Clinic Foundation, Cleveland, OH HUMANA PRESS TOTOWA, NEW JERSEY 4 Contents © 2001 Humana Press Inc. 999 Riverview Drive, Suite 208 Totowa, New Jersey 07512 For additional copies, pricing for bulk purchases, and/or information about other Humana titles, contact Humana at the above address or at any of the following numbers: Tel.: 973-256-1699; Fax: 973-256-8341; E-mail:[email protected]; Website: http://humanapress.com All rights reserved. No part of this book may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording, or otherwise without written permission from the Publisher. Due diligence has been taken by the publishers, editors, and authors of this book to assure the accuracy of the information published and to describe generally accepted practices. The contributors herein have carefully checked to ensure that the drug selections and dosages set forth in this text are accurate and in accord with the standards accepted at the time of publication. Notwithstanding, as new research, changes in government regulations, and knowledge from clinical experience relating to drug therapy and drug reactions constantly occurs, the reader is advised to check the product information provided by the manufacturer of each drug for any change in dosages or for additional warnings and contraindications. This is of utmost importance when the recommended drug herein is a new or infrequently used drug. It is the responsibility of the treating physician to determine dosages and treatment strategies for individual patients.
    [Show full text]
  • Drug Delivery System for Use in the Treatment Or Diagnosis of Neurological Disorders
    (19) TZZ __T (11) EP 2 774 991 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 10.09.2014 Bulletin 2014/37 C12N 15/86 (2006.01) A61K 48/00 (2006.01) (21) Application number: 13001491.3 (22) Date of filing: 22.03.2013 (84) Designated Contracting States: • Manninga, Heiko AL AT BE BG CH CY CZ DE DK EE ES FI FR GB 37073 Göttingen (DE) GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO •Götzke,Armin PL PT RO RS SE SI SK SM TR 97070 Würzburg (DE) Designated Extension States: • Glassmann, Alexander BA ME 50999 Köln (DE) (30) Priority: 06.03.2013 PCT/EP2013/000656 (74) Representative: von Renesse, Dorothea et al König-Szynka-Tilmann-von Renesse (71) Applicant: Life Science Inkubator Betriebs GmbH Patentanwälte Partnerschaft mbB & Co. KG Postfach 11 09 46 53175 Bonn (DE) 40509 Düsseldorf (DE) (72) Inventors: • Demina, Victoria 53175 Bonn (DE) (54) Drug delivery system for use in the treatment or diagnosis of neurological disorders (57) The invention relates to VLP derived from poly- ment or diagnosis of a neurological disease, in particular oma virus loaded with a drug (cargo) as a drug delivery multiple sclerosis, Parkinsons’s disease or Alzheimer’s system for transporting said drug into the CNS for treat- disease. EP 2 774 991 A1 Printed by Jouve, 75001 PARIS (FR) EP 2 774 991 A1 Description FIELD OF THE INVENTION 5 [0001] The invention relates to the use of virus like particles (VLP) of the type of human polyoma virus for use as drug delivery system for the treatment or diagnosis of neurological disorders.
    [Show full text]
  • Neuropathology and Which Upregulates P27
    296A ANNUAL MEETING ABSTRACTS 1357 p27, Cks1, Skp2 and PTEN Expression in Hepatocellular Design: The WA Department of Health (DOH) disseminated information about the Carcinoma program to healthcare providers throughout the state. Enrollment was prompted V Zolota, V Tzelepi, A Liava, N Pagoni, T Petsas, C Karatza, CD Scopa, AC Tsamandas. by healthcare providers contacting local or state DOH, the National Prion Disease University of Patras School of Medicine, Patras, Greece. Pathology Surveillance Center (NPDPSC), or the Univ of WA (UW) to report a case Background: p27Kip1 is a cell-cycle inhibitory protein and its downregulation is mediated of suspected prion disease. No case was declined and all costs, including transportation by its specific ubiqitin subunits Cks1 and Skp2. PTEN is a tumor suppressor gene of the deceased, were covered. Autopsies were performed by UW Neuropathology and which upregulates p27. This study investigates p27, Cks1, Skp2 and PTEN expression brains were evaluated at this site and the NPDPSC. in hepatocellular carcinoma (HCC). Results: During the first 30 months of surveillance, 30 cases of suspected prion disease Design: Formalin-fixed, paraffin-embedded 4µm sections, obtained from 67 HCC were referred. Eighteen had prion disease classified as CJD. One case was familial while hepatectomy specimens with matched non-neoplastic liver, were subjected to the remainder had sporadic (s) CJD of the following subtypes: eight M/M isoform 1, immunohistochemistry using monoclonal and polyclonal antibodies for p27, Cks1, two M/M isoforms 1-2, two M/V isoforms 1-2, two M/V isoform 2, one V/V isoforms Skp2 and PTEN. Nuclear staining was considered as positive.
    [Show full text]
  • Value of MR in Definition of the Neuropathology of Cerebral Palsy in Vivo
    Commentary _____________________________________________________________ Value of MR in Definition of the Neuropathology of Cerebral Palsy in Vivo Joseph J. Volpe1 Cerebral palsy refers to a clinical syndrome of Selective Neuronal Necrosis nonprogressive motor deficits (usually spastic Selective neuronal necrosis, a common expres­ weakness, uncommonly choreoathetosis, rarely sion of injury secondary to hypoxic-ischemic in­ ataxia) of central origin with onset from early sult in the term infant, is characterized by neu­ infancy. In this issue of the Journal, Truwit et al ronal destruction in a typical distribution (see ref. describe the MR findings in 40 patients with the 2 for review). Cerebral cortical neurons, particu­ clinical diagnosis of cerebral palsy (1). The pur­ larly those of the CA 1 region of hippocampus poses of their retrospective study were to define (Sommer's sector), are especially vulnerable. (In the anatomic substrates of cerebral palsy in the the premature infant, neuronal injury occurs prin­ living patient and, from the definitions of the cipally in inferior olivary nuclei, ventral pons, and topography of the neuropathology and the analy­ subiculum of hippocampus, although periventric­ sis of clinical data, to suggest etiology and timing ular white matter injury tends to be the predom­ of the brain injury. The authors place particular inant hypoxic-ischemic lesion in such infants.) emphasis on their conclusion that cerebral palsy The pathophysiology of the typical neuronal in­ is usually not related to perinatal factors. The jury of the term infant, ie, in hippocampus and work is relevant to the role of hypoxic-ischemic neocortex, is related predominantly to the re­ brain injury in the genesis of cerebral palsy, the gional distribution of excitatory synapses me­ means of diagnosis of hypoxic-ischemic brain diated by the excitotoxic amino acid glutamate injury in the neonatal period, the spectrum of the (see refs.
    [Show full text]